.: ORİJİNAL ARAŞTIRMA
The Effectiveness of Vaccines in Older Individuals Diagnosed with COVID-19: A Retrospective Cross-Sectional Study
COVID-19 Tanısı Alan Yaşlı Bireylerde Aşıların Etkinliği: Retrospektif Kesitsel Bir Çalışma
Turkiye Klinikleri J Health Sci. 2023;8(2):308-15
doi: 10.5336/healthsci.2022-94635
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: This study aimed to determine the effectiveness of vaccination status and vaccine types on the course and outcomes of the disease in the older individuals diagnosed with coronavirus disease-2019 (COVID-19). Material and Methods: The study included 1,258 individuals aged 65 years and older who were diagnosed with COVID-19 [polymerase chain reaction (PCR) test positive] between February and March 2022, and the study was conducted retrospectively. The vaccination status of the individuals, the types of vaccines administered to the individuals, and the number of vaccines were obtained from the Vaccine Tracking System. PCR results, hospitalization, and rates of death were obtained from the Public Health Management System. Results: Over 80 years of age was identified as a significant risk factor. In patients vaccinated with at least one dose of mRNA, the rate of intensive care unit treatment was 1%, and the rate of exitus was 0.2%. While 14% of individuals who had never been vaccinated were treated in the intensive care unit, all of these individuals became exitus. Among individuals vaccinated with at least 2 doses of inactivated vaccine, 6.4% were admitted to the intensive care unit, while 5% became exitus. It was determined that patients who received at least one dose of the mRNA vaccine were 93% protected from the need for intensive care and 99% protected from death. Conclusion: In terms of public health policies, appropriate vaccination, planning, and implementation of booster doses after vaccination are the most effective methods to protect older people from COVID-19.
Keywords: Aged; vaccination; COVID-19; inactivated vaccine; mRNA vaccine
Objective: This study aimed to determine the effectiveness of vaccination status and vaccine types on the course and outcomes of the disease in the older individuals diagnosed with coronavirus disease-2019 (COVID-19). Material and Methods: The study included 1,258 individuals aged 65 years and older who were diagnosed with COVID-19 [polymerase chain reaction (PCR) test positive] between February and March 2022, and the study was conducted retrospectively. The vaccination status of the individuals, the types of vaccines administered to the individuals, and the number of vaccines were obtained from the Vaccine Tracking System. PCR results, hospitalization, and rates of death were obtained from the Public Health Management System. Results: Over 80 years of age was identified as a significant risk factor. In patients vaccinated with at least one dose of mRNA, the rate of intensive care unit treatment was 1%, and the rate of exitus was 0.2%. While 14% of individuals who had never been vaccinated were treated in the intensive care unit, all of these individuals became exitus. Among individuals vaccinated with at least 2 doses of inactivated vaccine, 6.4% were admitted to the intensive care unit, while 5% became exitus. It was determined that patients who received at least one dose of the mRNA vaccine were 93% protected from the need for intensive care and 99% protected from death. Conclusion: In terms of public health policies, appropriate vaccination, planning, and implementation of booster doses after vaccination are the most effective methods to protect older people from COVID-19.
Keywords: Aged; vaccination; COVID-19; inactivated vaccine; mRNA vaccine
ÖZET
Amaç: Bu çalışmanın amacı, koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] tanısı almış yaşlı bireylerde aşılama durumları ve aşı çeşitlerinin hastalığın seyri ve sonuçları üzerindeki etkisini belirlemektir. Gereç ve Yöntemler: Çalışmaya Şubat-Mart 2022 tarihleri arasında COVID-19 [polimeraz zincir reaksiyonu (polymerase chain reaction ''PCR'') testi pozitif] tanısı konan 65 yaş ve üstü 1.258 birey dâhil edildi ve çalışma retrospektif olarak yapıldı. Bireylerin aşılanma durumları, bireylere uygulanan aşı türleri ve aşılanma sayıları Aşı Takip Sistemi'nden elde edildi. PCR sonuçları, hastaneye yatış ve ölüm oranları ise Halk Sağlığı Yönetim Sistemi'nden elde edildi. Bulgular: Seksen yaş üstü olmak önemli bir risk faktörü olarak belirlendi. En az bir doz mRNA ile aşılanan hastalarda yoğun bakımda tedavi görme oranı %1, eksitus oranı %0,2 idi. Hiç aşı yaptırmayan bireylerin %14'ü yoğun bakımda tedavi altına alınırken tamamı eksitus oldu. En az 2 doz inaktif aşı ile aşılanan bireylerin %6,4'ü yoğun bakıma yatarken, %5'i eksitus oldu. En az bir doz mRNA aşısı yapılan bireylerin, %93 oranında yoğun bakım ihtiyacından, %99 oranında ise ölümden korunduğu belirlendi. Sonuç: Halk sağlığı politikaları açısından uygun aşılama, planlama ve aşılama sonrası rapel dozların uygulanması yaşlı bireyleri COVID-19'dan korumada en etkili yöntemlerdir.
Anahtar Kelimeler: Yaşlı; aşılama; COVID-19; inaktive aşı; mRNA aşısı
Amaç: Bu çalışmanın amacı, koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] tanısı almış yaşlı bireylerde aşılama durumları ve aşı çeşitlerinin hastalığın seyri ve sonuçları üzerindeki etkisini belirlemektir. Gereç ve Yöntemler: Çalışmaya Şubat-Mart 2022 tarihleri arasında COVID-19 [polimeraz zincir reaksiyonu (polymerase chain reaction ''PCR'') testi pozitif] tanısı konan 65 yaş ve üstü 1.258 birey dâhil edildi ve çalışma retrospektif olarak yapıldı. Bireylerin aşılanma durumları, bireylere uygulanan aşı türleri ve aşılanma sayıları Aşı Takip Sistemi'nden elde edildi. PCR sonuçları, hastaneye yatış ve ölüm oranları ise Halk Sağlığı Yönetim Sistemi'nden elde edildi. Bulgular: Seksen yaş üstü olmak önemli bir risk faktörü olarak belirlendi. En az bir doz mRNA ile aşılanan hastalarda yoğun bakımda tedavi görme oranı %1, eksitus oranı %0,2 idi. Hiç aşı yaptırmayan bireylerin %14'ü yoğun bakımda tedavi altına alınırken tamamı eksitus oldu. En az 2 doz inaktif aşı ile aşılanan bireylerin %6,4'ü yoğun bakıma yatarken, %5'i eksitus oldu. En az bir doz mRNA aşısı yapılan bireylerin, %93 oranında yoğun bakım ihtiyacından, %99 oranında ise ölümden korunduğu belirlendi. Sonuç: Halk sağlığı politikaları açısından uygun aşılama, planlama ve aşılama sonrası rapel dozların uygulanması yaşlı bireyleri COVID-19'dan korumada en etkili yöntemlerdir.
Anahtar Kelimeler: Yaşlı; aşılama; COVID-19; inaktive aşı; mRNA aşısı
REFERANSLAR:
- WHO [Internet]. [Cited: October 20, 2022]. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: [Link]
- T.C. Sağlık Bakanlığı [İnternet]. [Erişim tarihi: 20 Ekim 2022]. COVID-19 Bilgilendirme. Erişim linki: [Link]
- Campbell A, Caul S. Deaths involving COVID-19, England and Wales deaths occurring in March 2020. Office for National Statistics. 2020. Cited: October 20, 2022. Available from: [Link]
- Center for Disease Control and Prevention. [Accessed 10.04.2023]. [Link]
- Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al; IVY Network; HAIVEN Investigators. Effectiveness of Pfizer-BioNTech and moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):674-9. [PubMed] [PMC]
- Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831-7. [Crossref] [PubMed] [PMC]
- CoVariants [Internet]. [Cited: October 20, 2022]. GISAID. Available from: [Link]
- Bayram A, Demirbakan H, Günel Karadeniz P, Erdoğan M, Koçer I. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021;93(9):5560-7. [Crossref] [PubMed] [PMC]
- Tabachnick BG, Fidell LS. Using Multivariate Statistics. 5th ed. Boston: Pearson College Div; 2006.
- Arregocés-Castillo L, Fernández-Ni-o J, Rojas-Botero M, Palacios-Clavijo A, Galvis-Pedraza M, Rincón-Medrano L, et al. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet Healthy Longev. 2022;3(4):e242-e52. Erratum in: Lancet Healthy Longev. 2022;3(8):e518. [Crossref] [PubMed] [PMC]
- Mazagatos C, Monge S, Olmedo C, Vega L, Gallego P, Martín-Merino E, et al; Working Group for the surveillance and control of COVID-19 in Spain; Working group for the surveillance and control of COVID-19 in Spain. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. Euro Surveill. 2021;26(24):2100452. [Crossref] [PubMed] [PMC]
- Cabezas C, Coma E, Mora-Fernandez N, Li X, Martinez-Marcos M, Fina F, et al. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study. The BMJ. 2021;374:n1868. [Crossref] [PubMed] [PMC]
- Nunes B, Rodrigues AP, Kislaya I, Cruz C, Peralta-Santos A, Lima J, et al. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. Euro Surveill. 2021;26(38):2100833. [Crossref] [PubMed] [PMC]
- Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in chile. N Engl J Med. 2021;385(10):875-84. [Crossref] [PubMed] [PMC]
- Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 vaccines over a 9-month period in north carolina. N Engl J Med. 2022;386(10):933-41. [Crossref] [PubMed] [PMC]
- Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386(4):340-50. [Crossref] [PubMed] [PMC]
- Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-57. [Crossref] [PubMed] [PMC]
- Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, et al. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021;600(7890):701-6. [Crossref] [PubMed]
- Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immunity & Ageing. 2019;16(1). [Crossref] [PubMed] [PMC]
- Ranzani OT, Hitchings MDT, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021 Aug 20;374:n2015. Erratum in: BMJ. 2021;374:n2091. [PubMed] [PMC]
- Nguyen NT, Chinn J, De Ferrante M, Kirby KA, Hohmann SF, Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLoS One. 2021;16(7):e0254066. [Crossref] [PubMed] [PMC]
- Ejaz R, Ashraf MT, Qadeer S, Irfan M, Azam A, Butt S, et al. Gender-based incidence, recovery period, and mortality rate of COVID-19 among the population of district Attock, Pakistan. Braz J Biol. 2021;83:e249125. [Crossref] [PubMed]
.: İşlem Listesi